Tags

Type your tag names separated by a space and hit enter

Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland.
Vaccine. 2011 Oct 06; 29(43):7463-73.V

Abstract

We evaluated the cost-effectiveness of universal infant rotavirus (RV) vaccination compared to current standard of care of "no vaccination". Two RV vaccines are currently licensed in Ireland: Rotarix and RotaTeq. A cohort model used in several European countries was adapted using Irish epidemiological, resource utilisation and cost data. The base case model considers the impact of Rotarix vaccination on health-related quality of life of children under five years old from a healthcare payer perspective. Other scenarios explored the use of RotaTeq, impact on one caregiver, on societal costs and on cases that do not seek medical attention. Cost was varied between the vaccine list price (€100/course) in the base case and an assumed tender price (€70/course). One-way and probabilistic sensitivity analyses were conducted. Implementing universal RV vaccination may prevent around 1970 GP visits, 3280 A&E attendances and 2490 hospitalisations. A vaccination programme was estimated to cost approximately €6.54 million per year but €4.65 million of this would be offset by reducing healthcare resource use. The baseline ICER was €112,048/QALY and €72,736/QALY from the healthcare payer and societal perspective, respectively, falling to €68,896 and €43,916/QALY, respectively, if the impact on one caregiver was considered. If the price fell to €70 per course, universal RV vaccination would be cost saving under all scenarios. Results were sensitive to vaccination costs, incidence of RV infection and direct medical costs. Universal RV vaccination would not be cost-effective under base case assumptions. However, it could be cost-effective at a lower vaccine price or from a wider societal perspective.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Tilson L
National Centre for Pharmacoeconomics, St. James' Hospital, Dublin 8, Ireland. ltilson@stjames.ie
Jit M
No affiliation info available
Schmitz S
No affiliation info available
Walsh C
No affiliation info available
Garvey P
No affiliation info available
McKeown P
No affiliation info available
Barry M
No affiliation info available

MeSH

Child, PreschoolCost-Benefit AnalysisGastroenteritisHumansInfantIrelandQuality of LifeRotavirusRotavirus InfectionsRotavirus Vaccines

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21821085

Citation

Tilson, L, et al. "Cost-effectiveness of Universal Rotavirus Vaccination in Reducing Rotavirus Gastroenteritis in Ireland." Vaccine, vol. 29, no. 43, 2011, pp. 7463-73.
Tilson L, Jit M, Schmitz S, et al. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland. Vaccine. 2011;29(43):7463-73.
Tilson, L., Jit, M., Schmitz, S., Walsh, C., Garvey, P., McKeown, P., & Barry, M. (2011). Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland. Vaccine, 29(43), 7463-73. https://doi.org/10.1016/j.vaccine.2011.07.056
Tilson L, et al. Cost-effectiveness of Universal Rotavirus Vaccination in Reducing Rotavirus Gastroenteritis in Ireland. Vaccine. 2011 Oct 6;29(43):7463-73. PubMed PMID: 21821085.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland. AU - Tilson,L, AU - Jit,M, AU - Schmitz,S, AU - Walsh,C, AU - Garvey,P, AU - McKeown,P, AU - Barry,M, Y1 - 2011/08/05/ PY - 2011/01/14/received PY - 2011/07/08/revised PY - 2011/07/17/accepted PY - 2011/8/9/entrez PY - 2011/8/9/pubmed PY - 2012/3/30/medline SP - 7463 EP - 73 JF - Vaccine JO - Vaccine VL - 29 IS - 43 N2 - We evaluated the cost-effectiveness of universal infant rotavirus (RV) vaccination compared to current standard of care of "no vaccination". Two RV vaccines are currently licensed in Ireland: Rotarix and RotaTeq. A cohort model used in several European countries was adapted using Irish epidemiological, resource utilisation and cost data. The base case model considers the impact of Rotarix vaccination on health-related quality of life of children under five years old from a healthcare payer perspective. Other scenarios explored the use of RotaTeq, impact on one caregiver, on societal costs and on cases that do not seek medical attention. Cost was varied between the vaccine list price (€100/course) in the base case and an assumed tender price (€70/course). One-way and probabilistic sensitivity analyses were conducted. Implementing universal RV vaccination may prevent around 1970 GP visits, 3280 A&E attendances and 2490 hospitalisations. A vaccination programme was estimated to cost approximately €6.54 million per year but €4.65 million of this would be offset by reducing healthcare resource use. The baseline ICER was €112,048/QALY and €72,736/QALY from the healthcare payer and societal perspective, respectively, falling to €68,896 and €43,916/QALY, respectively, if the impact on one caregiver was considered. If the price fell to €70 per course, universal RV vaccination would be cost saving under all scenarios. Results were sensitive to vaccination costs, incidence of RV infection and direct medical costs. Universal RV vaccination would not be cost-effective under base case assumptions. However, it could be cost-effective at a lower vaccine price or from a wider societal perspective. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/21821085/Cost_effectiveness_of_universal_rotavirus_vaccination_in_reducing_rotavirus_gastroenteritis_in_Ireland_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(11)01101-7 DB - PRIME DP - Unbound Medicine ER -